



A Journal of the Gesellschaft Deutscher Chemiker

Angewandte Chemie

GDCh

International Edition

www.angewandte.org

Accepted Article

Title: Copper-Catalyzed Asymmetric Arylation of N-Heteroaryl Aldimines via an Elementary Step of 1,4-Insertion

Authors: Jianrong Steve Zhou, Xurong Qin, Chunlin Wu, Hajime Hirao, and Adhitya Mangala Putra Moeljadi

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Angew. Chem. Int. Ed.* 10.1002/anie.201812646
Angew. Chem. 10.1002/ange.201812646

Link to VoR: <http://dx.doi.org/10.1002/anie.201812646>
<http://dx.doi.org/10.1002/ange.201812646>

Copper-Catalyzed Asymmetric Arylation of *N*-Heteroaryl Aldimines via an Elementary Step of 1,4-Insertion

Chunlin Wu,^{†a} Xurong Qin,^{†a} Adhitya Mangala Putra Moeljadi,^b Hajime Hirao^b and Jianrong Steve Zhou^{a*}

Abstract: Copper complexes of monodentate phosphoramidites efficiently promote asymmetric arylation of *N*-azaaryl aldimines with arylboroxines. DFT calculations and kinetic isotopic experiments support an elementary step of 1,4-insertion in the reaction pathway, in which an aryl-copper species adds directly across four atoms C=N-C=N in *N*-azaaryl aldimines.

Chiral alkylamines are important motifs in modern medicines and they are present in about 15% of blockbuster drugs. Therefore, efficient stereoselective synthesis of these compounds has received much attention amongst synthetic chemists.^[1] Of particular interest to us, chiral *N*-azaaryl alkylamines are present in quite a number of medicines and drug candidates (Figure 1). For example, ontazolast is a drug currently used for the treatment of inflammation.^[2] Chiral amine-substituted thiazole, pyrazole and imidazopyridazine are also found in many therapeutic agents that target depression, Alzheimer's disease and malaria.^[3] Moreover, aminopyrimidines are present in an isocitrate dehydrogenase (IDH) inhibitor^[4] and diflumetorim. The latter is a new-generation fungicide to protect wheat and barley.^[5]





Figure 1. Examples of chiral medicines and agrochemicals containing *N*-azaaryl amines.

Catalytic asymmetric arylation of imines using benchtop-stable arylboron reagents is a simple, convergent method to prepare chiral benzylic and benzhydryl amines from readily available reagents.^[6] For this reaction, noble metal catalysts, mostly based on rare and expensive rhodium^[7] and palladium,^[8] proved to be particularly effective, owing to efforts of Hayashi,^[9] Lin and Xu,^[10] Zhang,^[11] Manolikakes,^[12] and others.^[13] From a

mechanistic standpoint, both rhodium and palladium catalysts use 1,2-insertion of arylmetal species to imines.^[14] In most cases, imines activated with *N*-sulfonyl and *N*-sulfamoyl groups were used. Recently, chiral 1,1'-biphenols and thioureas were also used in asymmetric addition of arylborons to reactive α -iminoesters.^[15]




Scheme 1. Screening of chiral phosphoramidites for model arylation.

Initially, we attempted copper-catalyzed arylation of aldimines with arylboroxines and searched for chiral ancillary ligands (Scheme 1).^[16] Among a dozen of aldimines carrying different groups on the nitrogen atom that we have tested (see Schemes 5 and 6c), aldimine **1a** bearing an *N*-3-picoyl ring afforded the desired product in both good yield and excellent stereoselectivity. Thus, 10 mol% copper catalyst ligated by spiro-1,1'-diindanyl phosphoramidite **L**^[17] promoted arylation of *p*-tolylboroxine **2a** to deliver benzhydryl amine **3a** in 90% ee and 90% yield. Modification of the amine fragment of **L** failed to improve the stereoselectivity further unfortunately (**S1-4**). Later, we prepared ligand **L'** with inverted spiro chirality, which led to the opposite enantiomer of **3a** as the major isomer (-84% ee). Therefore, the spiro-backbone is the dominant stereo-determining element in the catalyst. Furthermore, two Feringa ligands **N1-2** only provided **3a** in moderate ee values. 0.5 equiv of *p*-tolylboroxines also gave **3a** in 85% yield after 2 days. Other arylboron reagents were also tested such as PhB(OH)₂, PhBF₃K, PhBpin and PhB(cat), which provided no desired product. As a note of caution, the reaction was sensitive to trace amounts of added water, so dry solvents must be used.


[a] Dr. C. Wu, Dr. X. Qin, Prof. Dr. J. S. Zhou
Division of Chemistry and Biological Chemistry
School of Physical and Mathematical Sciences
Nanyang Technological University, 21 Nanyang Link, SPMS-CBC-06-06, Singapore 637371
E-mail: jrzhou@ntu.edu.sg

[†] CW and XQ are co-first authors

[b] Dr. A. M. P. Moeljadi, Prof. Dr. H. Hirao
Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, China
Supporting information for this article is given via a link at the end of the document.



Scheme 2. Organoboroxines in asymmetric addition to **1a**.




Scheme 3. (a) Examples of arylation of aldimines. (b) A gram-scale arylation of an aldimine.

The optimized copper catalyst of ligand **L** was applicable to asymmetric arylation of aldimine **1a** using both electron-rich and poor aryl boroxines (**3a-i**) (Scheme 2). In particular, aryl fluorides, chlorides and bromides were well tolerated (**3c-e** and **3g**), but aryl iodides inhibited the desired transformation. In the reaction of *o*-tolyl boroxine, the corresponding product was obtained in good yield, albeit in moderate 66% ee. 4-Pyridyl boroxine did not react at all while 3-pyridyl analogues led to about 10% yield. Methyl boroxine did not react at all. Unfortunately, the addition of *trans*-styryl boroxine (**3j**) resulted in only moderate 50% ee.


Many aromatic aldimines of different electronic and steric properties on aryl rings also reacted smoothly with phenyl

boroxine (Scheme 3). Moreover, heterocycles such as thiophene, furan and benzofuran (**3n-q'**) were tolerated. We found that *sec*- and *tert*-alkyl aldimines (**3r'-s'**) also reacted well, but linear aliphatic aldehydes led to a complex mixture during aldimine formation. A brominated product **3e'** was suitable for single-crystal X-ray diffraction and its configuration was determined to be 1*S*.^[18] In a scale-up reaction, 2 mol% of the copper catalyst was sufficient to produce one gram of **3a** when the reaction temperature was raised from 80 to 100 °C (Scheme 3b). A simple crystallization readily improved optical purity of **3a'** to 99%. *N*-picolylamine **3a'** can be easily converted to the *N*-Boc amine via a reported procedure.^[19]

To streamline the synthesis of benzhydryl amines, we condensed 3-picolyl-2-amine and aryl aldehydes in the presence of a catalytic amount of tosylic acid together with molecular sieve (Scheme 4). The resulting aldimines were used directly, without purification, in the next step of catalytic arylation.^[20] At 110 °C, we found that 1 mol% copper catalyst was sufficient to achieve full conversion in all cases, which was accompanied by a slight drop of ee values.



Scheme 4. Streamlined arylation of aromatic aldimines.



Scheme 5. Streamlined arylation of other *N*-azaaryl aldimines.


Furthermore, a streamlined procedure was established for asymmetric synthesis of biaryl methylamines from other heteroaryl amines derived from pyrazine (**4a-i**), pyrimidine (**4j**), quinoline (**4k**), pyrazole (**4l-m**), 2-indazole (**4n**) and 2-benzisoxazole (Scheme 5). Herein, magnesium sulfate was used instead of molecular sieve, to improve the reproducibility of aldimine condensation. We found that the reactions in Scheme 5 were generally slower than those of *N*-2-picolyl aldimines; therefore, 5 mol% copper catalyst was needed to achieve good conversion at 110 °C, owing to relatively weak binding of these azacycles to the copper catalyst. Unfortunately, derivatives of azolyl amines of 1,3-oxazole, imidazole and 1,3-benzothiazole led to desired amines in good yields, but in 0-10% ee, probably because of competitive binding of these azoles to generate achiral copper catalysts.

We studied the insertion of phenylcopper(I) complex^[21] with a single phosphoramidite **L** into bound aldimine **1b**, using DFT calculations (B3LYP-D3(BJ)(SCRF)/B3LYP-D3(BJ)/B1 level) (Scheme 6a). In ground state **GS**, the coordination geometry around the copper center was trigonal planar. The three-coordinate organocopper(I) centers have been reported by others previously as key intermediates or as key fragments in copper-catalyzed reactions.^[22] Instead of classical 1,2-insertion,¹² we identified that 1,4-insertion of the copper-carbon bond into the core fragment of $\text{C}=\text{N}^2-\text{C}=\text{N}^1$ of **1b** was the more energetically favored pathway (Scheme 6a).^[23] The activation barrier leading to the major (*S*)-isomer was 7 kcalmol⁻¹. Moreover, the energy gap between two transition states **TS-S** and **TS-R** was 1.7 kcalmol⁻¹, in good agreement with the observed 93% ee. We also calculated 1,2-insertion pathways, which had much higher insertion barriers (21 and 23 kcalmol⁻¹ leading to (*R*)- and (*S*)-isomer), but it predicted the (*R*)-

enantiomer as the major, in contradiction with experimental results.

The 1,4-insertion step led to immediate product **Prod** with a partially *dearomatized* pyridine, which helped to disperse the negative charge on the iminyl nitrogen. Wiberg bond index analysis revealed that from **GS** to **Prod**, the bond order of N^1-C^2 decreased from 1.29 to 1.15, while that of N^2-C^2 increased significantly from 1.16 to 1.52.

The new 1,4-insertion mechanism also received some experimental support (Scheme 6). (a) The 3-methyl group on *N*-picolyl aldimines reinforced the *s-cisoid* reactive conformation of aldimines by exerting $\text{A}^{1,3}$ -type strain and thus accelerated the insertion process. Its omission or replacement at other positions on the *N*-pyridine resulted in much slower conversions (**3a2-4**). (b) The *N*-3-picolyl ketimine of acetophenone failed to react, because the iminyl methyl group disfavors the *s-cisoid* conformation. (c) All of other aldimines carrying *N*-anisyl (**3a5**), *N*-1-naphthyl, *N*-benzyl, *N*-Boc and *N*-Cbz groups lacked the ability to bind to the copper center, so did not react. (d) In a competition experiment leading to the formation of **3a6** and **3a7** carrying 4- CF_3 and 4-OMe groups on the *N*-pyridine ring, the former was formed much faster than the latter (42% yield versus 6% yield after 6 h), consistent with the important role played by the *N*-pyridine in stabilizing the developing negative charge during insertion. (e) All aldimines carrying other types of *N*-azacycles in Scheme 5 can easily undergo partial dearomatization to accommodate the negative charge. (f) A stoichiometric reaction between mesitylcopper(I), aldimine **1a** and ligand **L** (1 equiv) was performed in toluene (20 h at 110 °C). It resulted in 74% conversion and an adduct in <2% ee. In a background reaction, only 22% conversion was detected indicating ligand acceleration effect. (g) A Hammett plot was constructed for phenylation of several analogues of aromatic aldimine **1b** with different para-substituents on the aryl rings (OMe, Me, F, Cl and CF_3). A relatively large ρ value of +1.04 revealed a strong correlation between electron-deficient nature of aldimines and insertion rates.



Scheme 6. (a) 1,4-addition transition state **TS-S** leading to the major (*S*)-isomer. (b) Effect of different *N*-directing groups in aldimines on arylation and (c) substituents on *N*-pyridine group.

The DFT-optimized transition states indicated that the copper catalyst ligated with a single bulky phosphoramidite $L^{[24]}$ was sufficient for excellent enantiofacial induction during arylation. Ligand **L** adopted a specific baseball glove-like conformation, by minimizing steric interaction between its two large 1-phenylethyl groups (Figure 2). Consequently, one of them shielded the bottom-right quadrant (front view), whereas an aromatic ring of the spiro-diindanyl backbone pointed into the top-left space. Thus, the bottom-left quadrant was left widely open to house the reacting partners.




Figure 2. Transition state **TS-S** (left) and disfavored **TS-R** (right) for phenylation of **(L)(phenyl)Cu(I)** complex and bound aldimine **1b**. **L** is shown in space-filling representation and copper and other reacting ligands in ball-and-stick. Copper in magenta, carbon of Cu-bound phenyl ligand in green, nitrogen and carbon of aldimine **1b** in blue and pink.

In summary, we report the first example of catalytic enantioselective arylation of *N*-azaaryl aldimines using benchtop-stable arylboroxines, which affords pharmaceutically relevant chiral benzylic and benzydryl amines in excellent ee values.

Acknowledgement

We thank financial support from Nanyang Technological University, GSK-EDB Trust Fund (GSK-EDB Green and Sustainable Manufacturing Award 2017), A*STAR Science & Engineering Research Council (AME IRG A1783c0010), City University of Hong Kong (7200534 and 9610369) and National Science Foundation of China (21502157). CW and XQ contributed equally to the experiments. AMP and HH contributed DFT calculations of reaction pathways.


Keywords: copper catalysis • imine addition • chiral alkylamines • asymmetric arylation • heteroaromatic amines

References

- [1] a) *Amines: Synthesis, Properties and Applications* (Ed.: S. A. Lawrence), Cambridge University Press, **2005**; b) *Chiral Amine Synthesis* (Ed.: T. C. Nugent), Wiley-VCH, Weinheim, **2010**.
- [2] P. R. Farina, C. A. Homan, E. S. Lazer, T. P. Parks, "Discovery of BIRM 270: A New Class of Leukotriene Biosynthesis Inhibitors" in *The Search for Anti-Inflammatory Drugs: Case Histories from Concept to Clinic* (Eds.: V. J. Merluzzi, J. Adams), Birkhäuser Boston, Boston, **1995**, pp. 253.
- [3] a) D. H. Overstreet, G. Griebel, *Eur. J. Pharmacol.* **2004**, *497*, 49; b) C. Louis, C. Cohen, R. Depoortère, G. Griebel, *Neuropsychopharmacol.* **2006**, *31*, 2180; c) N. Boulloc, J. M. Large, E. Smiljanic, D. Whalley, K. H. Ansell, C. D. Edlin, J. S. Bryans, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5294; d) J. Qin, P. Dhondi, X. Huang, M. Mandal, Z. Zhao, D. Pissarnitski, W. Zhou, R. Aslanian, Z. Zhu, W. Greenlee, J. Clader, L. Zhang, M. Cohen-Williams, N. Jones, L. Hyde, A. Palani, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 664.
- [4] J. Yang, *Isocitrate dehydrogenase (IDH) inhibitors*, 2016, WO 2018/095344 A1.
- [5] Y. Yamanaka, M. Moritomo, K. Fujii, T. Tanaka, Y. Fukuda, K. Nishimura, *Pesticide Sci.* **1999**, *55*, 896.
- [6] a) S. Kobayashi, Y. Mori, J. S. Fossey, M. M. Salter, *Chem. Rev.* **2011**, *111*, 2626; b) C. S. Marques, A. J. Burke, *ChemCatChem* **2011**, *3*, 635; c) P. Tian, H.-Q. Dong, G.-Q. Lin, *ACS Catal.* **2012**, *2*, 95.
- [7] a) M. Kuriyama, T. Soeta, X. Hao, Q. Chen, K. Tomioka, *J. Am. Chem. Soc.* **2004**, *126*, 8128; b) R. B. C. Jagt, P. Y. Toullec, D. Geerdink, J. G. de Vries, B. L. Feringa, A. J. Minnaard, *Angew. Chem. Int. Ed.* **2006**, *45*, 2789; *Angew. Chem.* **2006**, *118*, 2855; c) K. Kurihara, Y. Yamamoto, N. Miyaura, *Adv. Synth. Catal.* **2009**, *351*, 260; d) Y. Luo, A. J. Carnell, H. W. Lam, *Angew. Chem. Int. Ed.* **2012**, *51*, 6762; *Angew. Chem.* **2012**, *124*, 6866; e) Y. Wang, Y. Liu, D. Zhang, H. Wei, M. Shi, F. Wang, *Angew. Chem. Int. Ed.* **2016**, *55*, 3776; *Angew. Chem.* **2016**, *128*, 3840; f) T. Yasukawa, T. Kuremoto, H. Miyamura, S. Kobayashi, *Org. Lett.* **2016**, *18*, 2716; g) G.-Z. Zhao, G. Sipos, A. Salvador, A. Ou, P. Gao, B. W. Skelton, R. Dorta, *Adv. Synth. Catal.* **2016**, *358*, 1759.
- [8] a) H. Dai, M. Yang, X. Lu, *Adv. Synth. Catal.* **2008**, *350*, 249; b) G.-N. Ma, T. Zhang, M. Shi, *Org. Lett.* **2009**, *11*, 875; c) J. Chen, X. Lu, W. Lou, Y. Ye, H. Jiang, W. Zeng, *J. Org. Chem.* **2012**, *77*, 8541; d) T. Johnson, M. Lautens, *Org. Lett.* **2013**, *15*, 4043; e) C. Schrapel, R. Peters, *Angew. Chem. Int. Ed.* **2015**, *54*, 10289; *Angew. Chem.* **2015**, *127*, 10428; f) Z. Yan, B. Wu, X. Gao, Y.-G. Zhou, *Chem. Commun.* **2016**, *52*, 10882.
- [9] a) N. Tokunaga, Y. Otomaru, K. Okamoto, K. Ueyama, R. Shintani, T. Hayashi, *J. Am. Chem. Soc.* **2004**, *126*, 13584; b) R. Shintani, M. Takeda, T. Tsuji, T. Hayashi, *J. Am. Chem. Soc.* **2010**, *132*, 13168; c) R. Shintani, M. Takeda, Y.-T. Soh, T. Ito, T. Hayashi, *Org. Lett.* **2011**, *13*, 2977; d) T. Nishimura, A. Noishiki, G. Chit Tsui, T. Hayashi, *J. Am. Chem. Soc.* **2012**, *134*, 5056; e) T. Nishimura, A. Noishiki, Y. Ebe, T. Hayashi, *Angew. Chem. Int. Ed.* **2013**, *52*, 1777; *Angew. Chem.* **2013**, *125*, 1821; f) C. Jiang, Y. Lu, T. Hayashi, *Angew. Chem. Int. Ed.* **2014**, *53*, 9936; *Angew. Chem.* **2014**, *126*, 10094.
- [10] a) Z.-Q. Wang, C.-G. Feng, M.-H. Xu, G.-Q. Lin, *J. Am. Chem. Soc.* **2007**, *129*, 5336; b) Z. Cui, H.-J. Yu, R.-F. Yang, W.-Y. Gao, C.-G. Feng, G.-Q. Lin, *J. Am. Chem. Soc.* **2011**, *133*, 12394; c) H. Wang, T. Jiang, M.-H. Xu, *J. Am. Chem. Soc.* **2013**, *135*, 971; d) T. Jiang, Z. Wang, M.-H. Xu, *Org. Lett.* **2015**, *17*, 528; e) Y. Li, Y.-N. Yu, M.-H. Xu, *ACS Catal.* **2016**, *6*, 661; f) T. Jiang, W.-W. Chen, M.-H. Xu, *Org. Lett.* **2017**, *19*, 2138.
- [11] a) G. Yang, W. Zhang, *Angew. Chem. Int. Ed.* **2013**, *52*, 7540; *Angew. Chem.* **2013**, *125*, 7688; b) Q. He, L. Wu, X. Kou, N. Butt, G. Yang, W. Zhang, *Org. Lett.* **2016**, *18*, 288.

- [12] a) T. Beisel, G. Manolikakes, *Org. Lett.* **2015**, *17*, 3162; b) T. Beisel, A. M. Diehl, G. Manolikakes, *Org. Lett.* **2016**, *18*, 4116.
- [13] M. Quan, L. Tang, J. Shen, G. Yang, W. Zhang, *Chem. Commun.* **2017**, 53, 609.
- [14] a) M. Quan, G. Yang, F. Xie, I. D. Gridnev, W. Zhang, *Org. Chem. Front.* **2015**, *2*, 398; b) N. Sieffert, J. Boisson, S. Py, *Chem. – Eur. J.* **2015**, *21*, 9753.
- [15] a) S. Lou, S. E. Schaus, *J. Am. Chem. Soc.* **2008**, *130*, 6922; b) W.-Y. Han, Z.-J. Wu, X.-M. Zhang, W.-C. Yuan, *Org. Lett.* **2012**, *14*, 976.
- [16] a) Copper/bipy-catalyzed addition of arylboroxines to *N*-tosylimines: Y.-X. Liao, Q.-S. Hu, *J. Org. Chem.* **2011**, *76*, 7602; b) R. Frauenlob, C. García, G. A. Bradshaw, H. M. Burke, E. Bergin, *J. Org. Chem.* **2012**, *77*, 4445; c) M. S. T. Morin, Y. Lu, D. A. Black, B. A. Arndtsen, *J. Org. Chem.* **2012**, *77*, 2013.
- [17] J.-H. Xie, Q.-L. Zhou, *Acc. Chem. Res.* **2008**, *41*, 581.
- [18] CCDC 1873584 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/data_request/cif.
- [19] N. Dastbaravardeh, K. Kirchner, M. Schnürch, M. D. Mihovilovic, *J. Org. Chem.* **2013**, *78*, 658.
- [20] a) N. R. Candeias, F. Montalbano, P. M. S. D. Cal, P. M. P. Gois, *Chem. Rev.* **2010**, *110*, 6169; b) C. A. Guerrero, T. R. Ryder, "The Petasis Borono-Mannich Multicomponent Reaction" in *Boron Reagents in Synthesis, Vol. 1236*, American Chemical Society, **2016**, pp. 275.
- [21] N. Yoshikai, E. Nakamura, *Chem. Rev.* **2012**, *112*, 2339.
- [22] a) H. Zhang, R. M. Gschwind, *Angew. Chem. Int. Ed.* **2006**, *45*, 6391; *Angew. Chem.* **2006**, *118*, 6540; b) F. von Rekowski, C. Koch, R. M. Gschwind, *J. Am. Chem. Soc.* **2014**, *136*, 11389; c) R. Ardkhean, P. M. C. Roth, R. M. Maksymowicz, A. Curran, Q. Peng, R. S. Paton, S. P. Fletcher, *ACS Catal.* **2017**, *7*, 6729; d) E. Rideau, H. You, M. Sidera, T. D. W. Claridge, S. P. Fletcher, *J. Am. Chem. Soc.* **2017**, *139*, 5614.
- [23] a) A. E. Dorigo, K. Morokuma, *J. Am. Chem. Soc.* **1989**, *111*, 4635; b) A. E. Dorigo, K. Morokuma, *J. Am. Chem. Soc.* **1989**, *111*, 6524; c) R. Yazaki, N. Kumagai, M. Shibasaki, *J. Am. Chem. Soc.* **2010**, *132*, 10275; d) R. Yazaki, N. Kumagai, M. Shibasaki, *Chem. – Asian J.* **2011**, *6*, 1778; e) C. Wu, G. Yue, C. D.-T. Nielsen, K. Xu, H. Hirao, J. Zhou, *J. Am. Chem. Soc.* **2016**, *138*, 742.
- [24] R. Ardkhean, P. M. C. Roth, R. M. Maksymowicz, A. Curran, Q. Peng, R. S. Paton, S. P. Fletcher, *ACS Catal.* **2017**, *7*, 6729.

N-heterocyclic nitrogen of aldimines is directly involved in 1,4-insertion of aryl-copper species



Chunlin Wu, Xurong Qin, Adhitya Mangala Putra Moeljadi, Hajime Hirao and Jianrong Steve Zhou*

Page No. – Page No.

Copper-Catalyzed Asymmetric Arylation of *N*-Heteroaryl Aldimines via an Elementary Step of 1,4-Insertion

Accepted Manuscript